PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study
![PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study](https://jnm.snmjournals.org/content/jnumed/64/3/386/F1.large.jpg?download=true)
PET imaging that targets fibroblast activation protein (FAP) on the surface of cancer-associated fibroblasts has yielded promising tumor diagnostic results. FAP-2286 contains cyclic peptides as FAP-binding motifs to optimize tumor retention compared with the small-molecule FAP inhibitor (FAPI) series (FAPI-04/46). The aim of this study was to evaluate the diagnostic accuracy of 68Ga-FAP-2286 to detect primary and metastatic lesions in patients with various types of cancer, compared with 18F-FDG and 68Ga-FAP-2286. Methods: Sixty-four patients with 15 types of cancer underwent 68Ga-FAP-2286 PET/CT for initial assessment or detection of recurrence. For comparison, 63 patients underwent paired 68Ga-FAP-2286 and 18F-FDG PET/CT and 19 patients underwent paired 68Ga-FAP-2286 and 68Ga-FAPI-46 PET/CT. Lesion uptake was quantified as SUVmax and tumor-to-background ratio. The Wilcoxon matched-pairs signed-rank test was used to compare SUVmax between PET modalities, and the McNemar test was used to compare lesion detectability. Results: Uptake of 68Ga-FAP-2286 was significantly higher than that of 18F-FDG in primary tumors (median SUVmax, 11.1 vs. 6.9; P < 0.001), lymph node metastases (median SUVmax, 10.6 vs. 6.2; P < 0.001), and distant metastases, resulting in improved image contrast and lesion detectability. All primary tumors (46/46) were clearly visualized by 68Ga-FAP-2286 PET/CT, whereas 9 of the 46 lesions could not be visualized by 18F-FDG PET/CT. The lesion detection rate of 68Ga-FAP-2286 PET/CT was superior to that of 18F-FDG PET/CT for involved lymph nodes (98% [105/107] vs. 85% [91/107], P = 0.001) and bone and visceral metastases (95% [162/171] vs. 67% [114/171], P < 0.001). 68Ga-FAP-2286 yielded tumor uptake and lesion detection rates similar to those of 68Ga-FAPI-46 in a subcohort of 19 patients. Conclusion: 68Ga-FAP-2286 is a promising FAP-inhibitor derivative for safe cancer diagnosis, staging, and restaging. It may be a better alternative to 18F-FDG for the cancer types that exhibit low-to-moderate uptake of 18F-FDG, which include gastric, pancreatic, and hepatic cancers. In addition, 68Ga-FAP-2286 and 68Ga-FAPI-46 yielded comparable clinical results.
![](https://jnm.snmjournals.org/content/jnumed/early/2023/09/07/jnumed.123.266046/F5.large.jpg)
Impact of 68Ga-FAPI PET/CT on Staging and Oncologic Management in
![](https://jnm.snmjournals.org/content/jnumed/64/3/386/F2.large.jpg)
PET Imaging of Fibroblast Activation Protein in Various Types of
![](https://pubs.rsna.org/cms/10.1148/radiol.212430/asset/images/medium/radiol.212430.va.gif)
68Ga Fibroblast Activation Protein Inhibitor PET/CT in the
![](https://jnm.snmjournals.org/content/jnumed/early/2023/05/04/jnumed.122.265383/F7.large.jpg)
Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast
![](https://www.mdpi.com/biomedicines/biomedicines-11-01350/article_deploy/html/images/biomedicines-11-01350-g001.png)
Biomedicines, Free Full-Text
![](https://pubs.rsna.org/cms/10.1148/radiol.2020203275/asset/images/medium/radiol.2020203275.va.gif)
Comparison of 68Ga-FAPI and 18F-FDG Uptake in Gastric, Duodenal
![](https://d3i71xaburhd42.cloudfront.net/f0b374cb95107deb34b02b9d332c6d61d28d8c12/18-Figure2-1.png)
PDF] Radiation Dosimetry and Biodistribution of 68Ga-FAPI-46 PET
![](https://jnm.snmjournals.org/content/jnumed/64/3/386/F1.large.jpg?download=true)
PET Imaging of Fibroblast Activation Protein in Various Types of
![](https://www.frontiersin.org/files/Articles/1291824/fbioe-11-1291824-HTML/image_m/fbioe-11-1291824-g001.jpg)
Frontiers Development of a fibroblast activation protein
![](https://jnm.snmjournals.org/content/jnumed/64/3/368/F1.large.jpg)
Novel 68Ga-FAPI PET/CT Offers Oncologic Staging Without COVID-19
![](https://media.springernature.com/m685/springer-static/image/art%3A10.1186%2Fs41181-021-00144-x/MediaObjects/41181_2021_144_Fig2_HTML.png)
18F-labeled tracers targeting fibroblast activation protein
![](https://www.frontiersin.org/files/Articles/924223/fonc-12-924223-HTML/image_m/fonc-12-924223-g001.jpg)
Frontiers Comparison of 68Ga-FAPI and 18F-FDG PET/CT in the
![](https://pubs.rsna.org/cms/10.1148/radiol.212430/asset/images/medium/radiol.212430.fig5.gif)
68Ga Fibroblast Activation Protein Inhibitor PET/CT in the